After two postponements, the 3rd stage test… Phase 3 is already underway in the UK
[EPA=연합뉴스]
(Washington = Yonhap News) Correspondent Ryu Ji-bok = US pharmaceutical company NovaVax announced on the 28th (local time) that it will begin a phase 3 clinical trial (phase 3) of a novel coronavirus infection (Corona 19) vaccine in the United States and Mexico.
It is the fifth pharmaceutical company that entered the third phase in the United States after Pfizer, Modena, AstraZeneca, and Johnson & Johnson.
According to CNN Broadcasting, Nova Bax’s 3rd phase targets 30,000 people over the age of 18.
Two-thirds of the participants receive the candidate vaccine twice every 21 days, and the rest receive a sham drug (placebo). All doses are monitored for 24 months after the second dose.
NovaVax is planning to conduct tests in areas with high rates of COVID-19 transmission so that the efficacy can be well observed.
By age group, people aged 65 and over account for at least 25%, and by race, at least 15% are black, 10-20% are Latino, and 1-2% are Native Americans.
Nova Baxes are currently in phase 3 in the UK and phase 2 in South Africa, and have been in phases 1 and 2 in the United States and Australia. These results are expected to come out in the first quarter of next year.
NovaVax was initially scheduled to enter phase 3 in the US in mid-October, but delayed twice due to the issue of expanding the vaccine manufacturing process.
NovaVax has agreed to provide 100 million doses in the US and 60 million doses in the UK. Korea is also negotiating with NovaVax regarding vaccine purchase.
So far, in the US, two vaccines made by Pfizer-Bioentech and Modena have been approved for emergency use and are being vaccinated. AstraZeneca entered the third phase in the United States in September last year, and Johnson & Johnson is expected to have a third phase result in January and February.
Unauthorized reproduction-redistribution prohibited>
2020/12/29 03:42 sent